Market Report -- In Play (SCLN)
November 30, 2009 4:05 PM ET
SciClone Pharma announces commencement and complete enrollment of clinical study examining ZADAXIN's ability to enhance the H1N1 vaccine SciClone Pharmaceuticals (SCLN) announced that Rome-based development partner Sigma-Tau, S.p.A., has initiated a pilot study in Italy to evaluate ZADAXIN's (thymalfasin) ability to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria from Novartis. The study, being conducted in hemodialysis patients, is now completely enrolled, having reached full enrollment after two days.
Top-line clinical results are expected by late 2009 or early 2010. Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
Read more In Play articles
Back to News Home
- MSN Money
- Search MSN Money
- Message Boards
- Site Status
For today's top Money video click here
E-mail this article
Print-friendly version
Discuss this article